“THE Co-Occurrence of Jak2 Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated With Combination of Tyrosine Kinase Inhibitors and Ruxolitinib.: Dual Myeloid Disorder Treated With Two Drug Association”. 2025. Mediterranean Journal of Hematology and Infectious Diseases 17 (1): e2025023. https://doi.org/10.4084/MJHID.2025.023.